NYMOX PHARMACEUTICAL CORPORATION (NYMXF) Net income 2015–2024
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$4.5MFY2024 · since FY2015: -$17.9M → -$4.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$4.5M | +49.2% |
| FY2023 | -$8.8M | -34.5% |
| FY2022 | -$6.6M | +47.5% |
| FY2021 | -$12.5M | -6.8% |
| FY2020 | -$11.7M | +10.8% |
| FY2019 | -$13.2M | -24.2% |
| FY2018 | -$10.6M | +21.1% |
| FY2017 | -$13.4M | -2.4% |
| FY2016 | -$13.1M | +26.7% |
| FY2015 | -$17.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NYMXF financial trends
NYMXF RevenueNYMXF Net marginNYMXF Gross profitNYMXF Gross marginNYMXF Operating incomeNYMXF Operating marginNYMXF Operating cash flowNYMXF Free cash flowNYMXF Capital expendituresNYMXF Return on equityNYMXF Stock buybacksNYMXF Dividends paidNYMXF Total assetsNYMXF Total liabilitiesNYMXF Shareholders’ equityNYMXF overview →